Keyphrases
IgG Antibody
100%
Neutralizing Antibodies
100%
BNT162b2
100%
Anti-RBD IgG
100%
Plasma Cell Disorders
100%
Confidence Interval
80%
Immunoglobulin G Antibodies
60%
Geometric Mean Titer
60%
Receptor-binding Domain
60%
Antireceptor
60%
Vaccine Dose
40%
BNT162b2 Vaccine
40%
Blood Samples
20%
Healthcare Workers
20%
Significant Predictors
20%
Antibody Response
20%
Patient Demographics
20%
Vaccination
20%
COVID-19
20%
Adverse Events
20%
Severe Morbidity
20%
Response to COVID-19
20%
Multivariable Logistic Regression
20%
COVID-19 Vaccination
20%
Antibody Titer
20%
Headache
20%
Adverse Events Following Immunization
20%
Injection Site Reaction
20%
Patients with Hematological Malignancies
20%
Humoral Response
20%
Medicine and Dentistry
Disease
100%
Immunoglobulin G Antibody
100%
Plasma Cell
100%
Neutralizing Antibody
100%
Receptor Binding
60%
Adverse Event
40%
mRNA Vaccine
40%
Hematologic Malignancy
20%
Logistic Regression Analysis
20%
Patient Population
20%
COVID-19 Vaccination
20%
COVID-19
20%
Headache
20%
Antibody Response
20%
Humoral Immunity
20%
Injection Site Reaction
20%
Biochemistry, Genetics and Molecular Biology
Immunoglobulin G
100%
Plasma Cell
100%
Neutralizing Antibody
100%
Titer
80%
Monospecific Antibody
60%
Immunoglobulin G
60%
Binding Domain
60%
Receptor Binding
60%
Messenger RNA
40%
Antibody Response
20%
Humoral Immunity
20%
Immunology and Microbiology
Immunoglobulin G Antibody
100%
Plasma Cell
100%
Neutralizing Antibody
100%
Vaccine Efficacy
80%
Vaccination Policy
60%
Titer
60%
Receptor Binding
60%
COVID-19
40%
Antibody Titer
20%
Antibody Response
20%
Humoral Immunity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Immunoglobulin G Antibody
100%
Neutralizing Antibody
100%
Vaccination Policy
60%
Receptor
60%
Adverse Event
40%
mRNA Vaccine
40%
Hematologic Malignancy
20%
Injection Site Reaction
20%
Headache
20%
Neuroscience
Immunoglobulin G Antibody
100%
Plasma Cell
100%
Neutralizing Antibody
100%
Receptor Binding
60%
Headache
20%
Humoral Immunity
20%